🏢 公司NewsroomLUNGCodex · 实盘不做把握 9/10
北京时间·源无时间·以抓取为准·⟳ 抓取 06:00:02·⚡ 决策 07-29 06:00:36 +34s·91.1 天前
Pulmonx 将于 7月29日盘后发布二季度财报并召开电话会
这只是公司例行财报发布时间和电话会预告，没有披露业绩数据、指引变化、订单或监管进展。
📄 原文LUNG↗ 原文
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader…
不做 Pulmonx（LUNG.US）
例行财报日程预告，无业绩数据、指引变化或其它方向性内容；当前不做，等正式财报披露后由新信号研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-15 · 扩散 low · price-in 风险 high ↗
关键理由
- 这只是公司例行财报发布时间和电话会预告，没有披露业绩数据、指引变化、订单或监管进展。
主要风险
- 真正可交易信息要等 2026-07-29 盘后财报数字和管理层指引披露后再判断。
原文全文
展开原文 · 1,637 字
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System and StratX
®
Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.pulmonx.com
.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System and StratX
®
Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.pulmonx.com
.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。